1918-78-1

Usage

Synthesis Reference(s)

Tetrahedron Letters, 21, p. 5051, 1980 DOI: 10.1016/S0040-4039(00)71130-0

InChI:InChI=1/C6H6O2S/c1-4-5(6(7)8)2-3-9-4/h2-3H,1H3,(H,7,8)

Upstream product

• 30319-05-2 3-bromo-2-methylthiophene 
• 765-50-4 2-Chloromethylthiophene 
• 541-41-3 chloroformic acid ethyl ester 
• 88-13-1 3-Thiophene carboxylic acid 
• 74-88-4 methyl iodide 
• 60-29-7 diethyl ether 
• 124-38-9 carbon dioxide 
• 109-72-8 n-butyllithium 
• 19432-66-7 ethyl 2-methyl-thiophene-3-carboxylate 
• 15719-64-9 methylammonium carbonate 
• 19432-64-5 2-thienylmagnesium chloride 

Downstream Products

• 857979-28-3 (2-methyl-3-thienyl)methanol 
• 1451-95-2 thiophene-2,3-dicarboxylic acid 
• 125790-51-4 2-(2-phenylethyl)thiophene-3-carboxylic acid 
• 53562-51-9 2-methylthiophene-3-carboxylic acid methyl ester 
• 1334598-73-0 C₁₃H₁₂O₄S₂ 
• 1334598-74-1 C₁₄H₁₄O₄S₂ 
• 1334598-77-4 C₁₃H₁₁NO₃S 
• 1334598-78-5 C₁₄H₁₃NO₃S 
• 1259396-11-6 methyl 5-bromo-2-methylthiophene-3-carboxylate 
• 1334598-41-2 C₁₅H₁₄O₃S 
• 1334598-43-4 C₁₆H₁₆O₃S 
• 1334598-50-3 C₁₄H₁₄O₄S₂ 
• 1334598-51-4 C₁₅H₁₆O₄S₂ 
• 1334598-54-7 C₁₄H₁₃NO₃S 

Relevant academic research and scientific papers

Synthesis and antimicrobial activity of some netropsin analogues

Nine novel lexitropsins were synthesized by linking two netropsin-like moieties through three different dicarboxylic acids; 9, 10-dihydro-2, 7-phenanthrenedicarboxylic acid; [(3- {[(carboxymethyl)amino]carbonyl}benzoyl) amino]acetic acid and indole-2,5-di

Discovery of a potent glucokinase activator with a favorable liver and pancreas distribution pattern for the treatment of type 2 diabetes mellitus

Glucokinase (GK) is an enzyme that plays an important role as a glucose sensor while maintaining whole body glucose homeostasis. Allosteric activators of GK (GKAs) have the potential to treat type 2 diabetes mellitus. To identify novel GKAs, a series of compounds based on a thiophenyl-pyrrolidine scaffold were designed and synthesized. In this series, compound 38 was found to inhibit glucose excursion in an oral glucose tolerance test (OGTT) in mice. Optimization of 38 using a zwitterion approach led to the identification of the novel GKA 59. GKA 59 exhibited potent blood glucose control in the OGTT test as well as a favorable safety profile. Owing to low pancreatic distribution, compound 59 primarily activates GK in the liver. This characteristic could overcome limitations of other GKAs, such as hypoglycemia, increased plasma triglycerides, and loss of efficacy.

Design, synthesis, and structure-activity relationship studies of novel thienopyrrolidone derivatives with strong antifungal activity against Aspergillus fumigates

In order to further enhance the anti-Aspergillus efficacy of our previously discovered antifungal lead compounds (I), two series of novel azoles featuring thieno[2,3-c]pyrrolidone and thieno[3,2-c]pyrrolidone nuclei were designed and evaluated for their in vitro activity on the basis of the binding mode of albaconazole using molecular docking, along with SARs of antifungal triazoles. Most of target compounds exhibited excellent activity against Candida and Cryptococcus spp., with MIC values in the range of 0.0625 μg/ml to 0.0156 μg/ml. The thieno[3,2-c]pyrrolidone unit was more suited for improving activity against Aspergillus spp. The most potent compound, 18a, was selected for further development due to its significant in vitro activity against Aspergillus spp. (MIC Combining double low line 0.25 μg/ml), as well as its high metabolic stability in human liver microsomes.

Convenient method for the preparation of the 2-methyl thiophen-3-yl magnesium bromide lithium chloride complex and its application to the synthesis of 3-substituted 2-methylthiophenes

Lithium chloride was found to accelerate formation of the Grignard reagent from inactive 3-bromo-2-methylthiophene (1) and commercial magnesium metal. Based on this finding, a convenient and potentially scalable preparation of ethyl 2-methylthiophene-3-ca

NOVEL THIOPHENECARBOXAMIDE DERIVATIVE AND PHARMACEUTICAL USE THEREOF

The object of the present invention is to provide a compound having a glucokinase-activating effect. A pharmaceutical composition comprising a compound represented by the general formula (I) or a pharmaceutically acceptable salt thereof as an active ingredient: wherein X means a nitrogen atom or CR6, wherein R6 means a hydrogen atom or a halogen atom; R1 means a hydrogen atom, a C1-C6 alkyl group, a C1-C6 alkoxy group or a C1-C6 alkylthio group; R2 means a hydrogen atom or a fluorine atom; R3 means a hydrogen atom or a C1-C6 alkyl group; and one of R4 and R5 means a hydrogen atom or a C1-C6 alkyl group, and the other means a C1-C6 alkylenecarboxylic acid, a C1-C6 alkylsulfonyl group, a C1-C6 alkylcarbonyl group, or CONH2.

Discovery and hit-to-lead optimization of novel allosteric glucokinase activators

We report on a hit generation and hit-to-lead program of a novel class of glucokinase activators (GKAs). Hit compounds, activators at low glucose concentration only were identified by vHTS. Scaffold modification reliably afforded activators also at high s

Amino-5-(5-membered)hetero-arylimidazolone compounds and the use thereof for beta-secretase modulation

The present invention provides a 2-amino-5-heteroaryl-5-phenylimidazolone compound of formula I The present invention also provides methods for the use thereof to inhibit β-secretase (BACE) and treat β-amyloid deposits and neurofibrillary tangles

Benzimidazole compounds and their use as estrogen agonists/antagonists

This invention relates to compounds, in particular benzimidazoles, that are useful as estrogen agonists and/or antagonists and pharmaceutical uses thereof. The present invention also relates to benzimidazoles that are selective for the ERβ receptor and pharmaceutical uses thereof.

BENZIMIDAZOLE COMPOUNDS AND THEIR USE AS ESTROGEN AGONISTS/ANTAGONISTS

This invention relates to compounds, in particular benzimidazoles, that are useful as estrogen agonists and/or antagonists and pharmaceutical uses thereof. The present invention also relates to benzimidazoles that are selective for the ER? receptor and pharmaceutical uses thereof.

Fused pyridine derivatives

The present provides a condensed pyridine compound (I) represented by the following formula: (wherein, R2represents ring A represents benzene ring, pyridine ring, thiophene ring or furan ring; and B represents its pharmaceutically acceptable salt or hydrates thereof, which is a clinically useful medicament having a serotonin antagonism, in particular, that for treating, ameliorating or preventing spastic paralysis or central muscle relaxants for ameliorating myotonia.